GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Debt-to-Equity

Imunon (Imunon) Debt-to-Equity : 0.12 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Imunon Debt-to-Equity?

Imunon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.49 Mil. Imunon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.14 Mil. Imunon's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $13.39 Mil. Imunon's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Imunon's Debt-to-Equity or its related term are showing as below:

IMNN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12   Med: 0.32   Max: 0.78
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of Imunon was 0.78. The lowest was 0.12. And the median was 0.32.

IMNN's Debt-to-Equity is ranked better than
55.33% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs IMNN: 0.12

Imunon Debt-to-Equity Historical Data

The historical data trend for Imunon's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Debt-to-Equity Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.33 0.12 0.21 0.12

Imunon Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.28 0.06 0.10 0.12

Competitive Comparison of Imunon's Debt-to-Equity

For the Biotechnology subindustry, Imunon's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Imunon's Debt-to-Equity falls into.



Imunon Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Imunon's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Imunon's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imunon  (NAS:IMNN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Imunon Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Imunon's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon (Imunon) Business Description

Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107